Fig. 4 | Signal Transduction and Targeted Therapy

Fig. 4

From: A potent neutralizing antibody provides protection against SARS-CoV-2 Omicron and Delta variants via nasal delivery

Fig. 4

Intranasally delivered 58G6 offers protection against the Omicron variant in a hamster model. a Animal experimental scheme. Hamsters were divided into 3 groups (n = 3 per group), including Group 1 (3-dose antibody treatment at 30 min pre-infection and 24 and 48 h post-infection), Group 2 (3-dose antibody treatment group at 3, 24, and 48 h post-infection), and Group 3 (control group administered PBS). Viral RNA in the b nasal washes, c respiratory tracts and d throat swabs of hamsters challenged with the Omicron variant at 3 dpi. e The number of infectious viruses (PFUs) was measured in the respiratory tract at 3 dpi by the viral plaque assay in Vero E6 cells. The geometric mean along with the standard deviation is plotted on the graph.

Back to article page